Abstract
Survivin is an important protein in regulating both cell apoptosis and proliferation. It has attracted growing attentions in recent years as a promising target for cancer therapy. Previous studies have revealed that monomeric survivin regulated apoptosis in a more significant way than the wild-type survivin that generally contains a large portion of its dimers. In order to investigate the roles of monomeric mutant survivin apoptosis and cell cycle regulation of human cancer cells, we developed and tested three dominant-negative mutants with multisite mutations (MSM) including TAT-survivin34/101/102, TAT-survivin34/117/101/102 and TAT-survivin117/101/102. Results revealed that MSM mutants remained as monomers under ambient conditions, and induced cells (breast cancer Bcap-37 cells) apoptosis even more efficiently, primarily through the caspase-dependent and Bcl-2-related pathways, than non-monomeric mutants. We further identified that the TAT-survivin34/101/102 and TAT-survivin117/101/102 MSM significantly inhibited the proliferation of Bcap-37 cells and arrested cells in S and G2/M phases, while TAT-survivin34/117/101/102 arrested cells in G2/M phase. It appeared to us that TAT-survivin34/101/102 and TAT-survivin117/101/102 also inhibited cell proliferation more significantly. These findings suggest that such MSM afford monomeric survivin with promising potentials for cancer therapy.
Original language | English (US) |
---|---|
Pages (from-to) | 111-118 |
Number of pages | 8 |
Journal | Biomedicine and Pharmacotherapy |
Volume | 69 |
DOIs | |
State | Published - Feb 1 2015 |
Bibliographical note
Publisher Copyright:© 2014 Elsevier Masson SAS.
Keywords
- Apoptosis
- Breast cancer
- Cell cycle regulation
- Protein engineering
- Site-specific mutagenesis
- Survivin